Advertisement

Topics

Psylin Neurosciences, Inc. Company Profile

13:51 EDT 21st September 2018 | BioPortfolio

Psylin Neurosciences, Inc. was formed in January, 2007 as a 50/50 joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. Psylin's mission is to pioneer the development of peptide therapeutics in neuropsychiatric disorders. Psylin has access to molecules in Amylin's PHORMOL library and to PsychoGenics' proprietary drug discovery technologies. Amylin's expertise in peptide biology, manufacturing and drug delivery, combined with PsychoGenics' expertise in preclinical neuropharmacology, provide Psylin with a unique drug discovery resource. Psylin has the right to develop a number of drug candidates in psychiatric disorders emerging from this collaboration.


News Articles [48 Associated News Articles listed on BioPortfolio]

Minerva Neurosciences, Inc: Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)

WALTHAM, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...

Minerva Neurosciences, Inc: Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates

Five ongoing late-stage trials on track for data readouts in 2019WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical com...

Minerva Neurosciences, Inc.: Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018

Management to host conference call WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the developmen...

Minerva Neurosciences, Inc.: Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018

Management to host conference call WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the developme...

Magnolia Neurosciences Launches with $31 Million

Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.

Minerva Neurosciences, Inc.: Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates

Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward Management to host conference call today at 8...

Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor

Minerva Neurosciences (NASDAQ:NERV) has announced findings from a pre-clinical study that show findings of the effect of roloperidone MIN-101) on brain-derived neurotrophic factor (BDNF). As quoted in...

Investor Network: Minerva Neurosciences Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Minerva Neurosciences Inc (NASDAQ: NERV) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 8:30 AM Eas...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Myobloc [Solstice Neurosciences, LLC]

Myobloc (rimabotulinumtoxinB) Injection

Clinical Trials [10 Associated Clinical Trials listed on BioPortfolio]

Enhancing Social Interaction With an AlterEgo Artificial Agent

The objective of AlterEgo is the creation of an interactive cognitive architecture, implementable in various artificial agents, allowing a continuous interaction with patients suffering fr...

Neurosciences-Intensive Care Unit Electrical Stimulation

Patients admitted to the Neurosciences Intensive Care Unit (NSICU) are at particular risk of developing ICU-associated weakness and myopathy, given the unique risks of early mobilization i...

Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies

The project will improve scientific knowledge regarding a recent law applying potentially to every french driver. It will give for the first time an indication on the impact of alerting tr...

Digital Cognition in Multiple Sclerosis

A DIGITAL THERAPEUTIC TO IMPROVE THINKING IN MULTIPLE SCLEROSIS WHO: 65 participants with a confirmed diagnosis of Multiple Sclerosis (MS) WHY: Purpose of the study is to compare the eff...

Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers

The development of a new automated method of measurement of the volume of the hippocampus allows confirming these results in patients presenting with pre-dementia AD, treated with donepezi...

Companies [51 Associated Companies listed on BioPortfolio]

Psylin Neurosciences, Inc.

Psylin Neurosciences, Inc. was formed in January, 2007 as a 50/50 joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. Psylin's mission is to pioneer the...

Merz Neurosciences

Merz Neurosciences is a division of Merz North America, a specialty healthcare company that develops and commercializes treatment solutions in aesthetics, dermatology and neurosci...

Nautilus Neurosciences, Inc.

Nautilus Neurosciences, Inc. is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with medically relevant products and services ...

Ester Neurosciences Ltd

Ester Neurosciences Ltd. is a development stage biopharmaceutical company committed to the discovery and development of novel therapeutic products for the treatment of neurological disorders such as m...

Knopp Neurosciences Inc.

Knopp Neurosciences, based in Pittsburgh, PA, USA, is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through inn...

More Information about "Psylin Neurosciences, Inc." on BioPortfolio

We have published hundreds of Psylin Neurosciences, Inc. news stories on BioPortfolio along with dozens of Psylin Neurosciences, Inc. Clinical Trials and PubMed Articles about Psylin Neurosciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Psylin Neurosciences, Inc. Companies in our database. You can also find out about relevant Psylin Neurosciences, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record